# EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC

> **NCT07637448** · PHASE2 · RECRUITING · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 32 (estimated)

## Conditions studied

- Lung Cancer Non-Small Cell Cancer (NSCLC)
- EGFR Activating Mutation
- PD-1 Antibody

## Interventions

- **DRUG:** EGFR-TKIs Combined with PD-1 Monoclonal Antibody

## Key facts

- **NCT ID:** NCT07637448
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-21
- **Primary completion:** 2029-03-01
- **Final completion:** 2030-03-01
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07637448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07637448, "EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07637448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*